Skip to content

PPDTM CorEvitasTM Vitiligo Drug Safety and Effectiveness Registry for Adults & Adolescents

PPDTM CorEvitasTM Vitiligo Drug Safety and Effectiveness Registry for Adults & Adolescents

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07659418
Enrollment
2500
Registered
2026-06-22
Start date
2026-08-21
Completion date
2099-12-31
Last updated
2026-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

The design is a prospective, observational (non-interventional) registry for adolescent and adult subjects with NSV under the care of a dermatology provider.

Detailed description

The objective of the registry is to create a cohort of adult and adolescent nonsegmental vitiligo (NSV) subjects to evaluate long-term real-world safety and effectiveness of standard of care treatments for NSV. Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to: characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of NSV, providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs.

Interventions

None listed

Sponsors

CorEvitas
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Individuals are eligible for enrollment if they meet all of the following criteria: * Have a dermatologist- or qualified dermatology practitioner-confirmed diagnosis of nonsegmental vitiligo (NSV). * Is at least 12 years of age or older at the time of enrollment. * Is willing and able to provide informed consent or assent, with parent/legal guardian consent as applicable. * Adult participants are willing and able to provide required personal information • Full legal name, sex, date of birth, and home ZIP/postal code * Meet the criteria for one of the following enrollment cohorts at the time of enrollment: Cohort 1: Eligible Medication Initiators - Individuals initiating a prescribed eligible NSV medication at the time of enrollment. Cohort 2: Not Initiating Eligible Medication - Individuals not currently receiving NSV medication at the time of enrollment, Individuals receiving eligible NSV medication prior to enrollment.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in the registry: \- Is participating or planning to participate in a blinded clinical trial for a vitiligo therapy.

Design outcomes

Primary

MeasureTime frameDescription
Vitiligo Epidemiology and presentationEvery 6 months for 10 years]The major clinical outcome include an assessment of the epidemiology of Vitiligo. This will be determined using PROs and ClinROs which will be included as part of the case report forms.

Countries

United States

Contacts

CONTACTVitiligo Registry Study Team
VITregistry@thermofisher.com508-408-5531

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 27, 2026